Dec 03, 2020
SMA Technologies announces release of OpCon version 20
Jun 19, 2020
Global Spinal Muscular Atrophy Market Outlook to 2027 - Advent of Oral mRNA Splicer for Treatment
Jun 12, 2020
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy
May 11, 2020
Save Nil's Life: Crowdfunding Campaign Created in Fight Against Spinal Muscular Atrophy (SMA) Type 2
Apr 28, 2020
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy
Apr 07, 2020
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
Feb 06, 2020
SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy
Jan 23, 2020
Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy
Dec 24, 2019
Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
Nov 21, 2019
Global spinal muscular atrophy treatment market is expected to grow with a CAGR of 12.9% over the forecast period from 2019-2025
Nov 11, 2019
Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy
Sep 30, 2019
Global Spinal Muscular Atrophy (SMA) Market Insights, Epidemiology and Market Forecast Report 2017-2019 & 2028
Jul 01, 2019
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
May 24, 2019
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
May 24, 2019
FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality
May 07, 2019
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
May 05, 2019
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Apr 25, 2019
Spinal Muscular Atrophy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Apr 22, 2019
Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA(TM) (nusinersen)
Mar 19, 2019
SMA Treatment Market Size Worth $3.9 Billion by 2025 | CAGR 12.9%: Grand View Research, Inc.